Recently in South Dakota, ACS CAN advocated for legislation to enhance patient access to biosimilar drugs, which offer safe and effective treatment options for many diseases including cancer.
According to a new edition of the ACS CAN report How Do You Measure Up? released today, most state legislatures are missing opportunities to enact laws and policies that could not only save lives, but also generate new revenue and long-term health care savings.
Unfortunately, for most of you the answer to the question above is not well. According to a new edition of the ACS CAN report How Do You Measure Up? released today, many state legislatures are missing opportunities to enact laws and policies that could not only generate new revenue and long-term health savings, but also save lives.
A new edition of the ACS CAN report How Do You Measure Up? shows that the majority of states are not measuring up on legislative solutions to prevent and fight cancer. The report ranks where states stand on these issues that play a critical role in reducing cancer incidence and death. It measures seven specific issues.
When you think of a friend or loved one who is battling cancer, you probably imagine their chemotherapy being administered intravenously at a local hospital. However, modern advances in technology and pharmaceuticals have produced chemotherapy drugs that can be taken orally, in pill form. To date, the FDA has approved more than 40 oral anti-cancer medications for the treatment of at least 54 different types of cancer.